Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that they have executed agreements with two existing investors, including John K. Scott, Jr. (collectively, the "Investors"), to purchase approximately 4.0 million shares of the Company’s… Read More..
PRINCETON, N.J.Feb. 13, 2020/PRNewswire/-- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its RiVax® (heat stable ricin toxin vaccine) development program for prevention of ricin intoxication has… Read More..
Assays expected to be capable of broad-based fecal pathogen identification in minutes for diagnosing infections in dogs and cats - complementary to Zomedica’s development work related to urine pathogens ANN ARBOR, Mich., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM)(“Zomedica” or “Company”), a veterinary diagnostic company, announced today… Read More..